Observational studyOpen heart2026
Comparing bridging drug therapy approaches prior to balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a prospective analysis from the national UK CURATE registry.
Observational study in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) medical therapies are commonly used as a bridge to balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic PH (CTEPH) but their effectiveness remains unclear. We investigated the impact of different bridging therapies in patients undergoing BPA.
methodsThis secondary analysis of the prospective CTEPD UK Registry to Assess Treatments and OutcomEs registry evaluated the impact of different PH medical therapies on haemodynamic and physiological parameters in the UK's national CTEPH cohort. Consecutive patients undergoing first BPA at Royal Papworth Hospital between October 2015 and October 2024 were included. Baseline parameters were assessed at CTEPH diagnosis and after initiating bridging PH medical therapy prior to BPA. Periprocedural complications at first BPA were compared between groups.
resultsHaemodynamic and functional parameters of 158 patients were analysed. Patients managed with phosphodiesterase-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA) dual therapy had higher baseline mean pulmonary artery pressure (mPAP, p=0.019), right atrial pressure (RAP, p=0.038) and pulmonary vascular resistance (PVR, p=0.004) and lower cardiac output (CO, p=0.017) and cardiac index (CI, p=0.029) versus PDE5i or riociguat monotherapy. Dual therapy was associated with a greater percentage increase in CI (40% vs 13% vs 16%, p<0.001) and CO (34% vs 8% vs 14%, p<0.001) and a greater percentage decrease in PVR (-39% vs -30% vs -25%, p=0.008) and N-terminal pro-B-type natriuretic peptide (-67% vs -21% vs -32%, p=0.004) compared with PDE5i monotherapy and riociguat monotherapy. These differences persisted after multivariable adjustment for baseline haemodynamic severity. Lung injury occurred more frequently in patients with higher PVR (>540 dynes·s·cm⁻⁵, p=0.049) and mPAP (>40 mm Hg, p=0.001) at first BPA. Periprocedural complication rates at first BPA were similar between bridging strategies.
conclusionsBridging with PH medical therapies to first BPA was associated with improved haemodynamic parameters in this real-world observational study. PDE5i and ERA dual therapy was associated with greater haemodynamic improvement than monotherapy with PDE5i or riociguat, without differences in complication rates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.